While CAR T cells are a promising treatment option for several cancers, clinical translation is often complicated by on-target, off-tumor side effects. Standard viability assays successfully identify cytotoxicity, but they routinely miss the earlier functional side effects that precede cell death.
This application note details a dual-modality in vitro model for capturing both viability and electrophysiology, allowing researchers to properly evaluate safety prior to clinical use.
Download the application note to explore
- A more complete approach to evaluating side effects associated with immunotherapies
- A HER2-CAR T and iPSC-derived cardiomyocyte model for tracking on-target, off-tumor toxicity
- Methods for distinguishing antigen-specific effects from nonspecific toxicity
